Precocious Puberty

  • Anil Bhansali
  • Anuradha Aggarwal
  • Girish Parthan
  • Yashpal Gogate


A 3-year-old girl was brought by her mother with the complaint of progressive development of breast for the last 6 months. It was not accompanied with appearance of pubic hair or history of vaginal bleed, though there was history of vaginal discharge occasionally. It was also noticed that she had sudden increase in her height over the last 6 months. There was no history of “waxing and waning” in the breast size. She did not have history of headache, visual disturbances, seizures, head injury, meningitis/encephalitis, cranial irradiation, pain in the abdomen, or palpable abdominal mass. She did not have symptoms suggestive of hypothyroidism. There was no history of any drug intake or use of estrogen or “hormone dust” exposure. On examination, her height was 103 cm (97th percentile, +2SDS) and weight 15 Kg (75th percentile), with a target height of 159 cm (25th percentile). She did not have cafe-au-lait macule, adenoma sebaceum, shagreen patch, neurofibroma, or bony deformity. She had no goiter and deep tendon reflexes were normal. Visual field and acuity were normal. Her Tanner staging was A−, P1, B3. Systemic examination was unremarkable. On investigations, hormonal profile revealed serum LH 2.3 mIU/ml (N < 0.3), FSH 3.9 mIU/ml, 17 β-estradiol 78.4 pg/ml (N < 10), T4 6.7 μg/dl (N 4.8–12.7), TSH 1.38 μIU/ml (N 0.27–4.2), and prolactin 21.2 ng/ml (N 4.7–23.3). GnRH agonist stimulation test (triptorelin 0.1 mg/m2) showed serum LH 56.3 mIU/ml at 3 h and 17 β-estradiol 185.3 pg/ml at 24 h. Her bone age was 7 years (Greulich and Pyle). Ultrasonography of the pelvis showed uterine length 4.1 cm and ovarian volume of 3 ml (right) and 1.5 ml (left) with multiple follicles. CEMRI sella showed convex upper border of anterior pituitary and the rest of the other areas were normal. With this clinical and biochemical profile, a diagnosis of idiopathic gonadotropin-dependent precocious puberty (GDPP) was considered and the patient was initiated with depot leuprolide (3.75 mg monthly). At 3 months of follow-up, she did not have a flare and had regression of secondary sexual characteristics (B3 to B2). Serum LH, basal and stimulated (3 h after the next dose of injection), was 1.7 mIU/ml and 14.7 mIU/ml, respectively. Basal serum estradiol was 23.7 pg/ml. The dose of depot leuprolide was increased to 7.5 mg once a month and advised to have a regular follow-up at three monthly intervals (Fig. 6.1).


Congenital Adrenal Hyperplasia GnRH Agonist Precocious Puberty Pubic Hair Secondary Sexual Characteristic 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Further Readings

  1. 1.
    Carel JC, Lahlou N, Roger M, Chaussain JL. Precocious puberty and statural growth. Human Reprod Update. 2004;10:135–47.CrossRefGoogle Scholar
  2. 2.
    Carel J, Léger J. Precocious puberty. N Engl J Med. 2008;358:2366–77.CrossRefPubMedGoogle Scholar
  3. 3.
    Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, Chaussain JL, Group T.F.t.s. Final height after long-term treatment with triptorelin slow-release for central precocious puberty: importance of statural growth after interruption of treatment. J Clin Endocrinol Metab. 1999;84:1973–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Carel JC, et al. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of decapeptyl in precocious puberty. J Clin Endocrinol Metab. 1999;84:1973–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Cesario SK, Hughes LA. Precocious puberty: a comprehensive review of literature. J Obstet Gynecol Neonatal Nurs. 2007;36:263–74.CrossRefPubMedGoogle Scholar
  6. 6.
    DeGroot L, Jameson J. Endocrinology. Philadelphia: Saunders/Elsevier; 2010.Google Scholar
  7. 7.
    Dumitrescu CE, Collins MT. McCune-Albright syndrome. Orphanet J Rare Dis. 2008;3:12.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Freire A, Escobar M, Gryngarten M, Arcari A, Ballerini M, Bergadá I, et al. High diagnostic accuracy of subcutaneous Triptorelin test compared with GnRH test for diagnosing central precocious puberty in girls. Clin Endocrinol. 2013;78:398–404.CrossRefGoogle Scholar
  9. 9.
    Kaplowitz P, Oberfield S. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Pediatrics. 1999;104:936–41.CrossRefPubMedGoogle Scholar
  10. 10.
    Melmed S, Williams R. Williams textbook of endocrinology. Philadelphia: Elsevier/Saunders; 2011.Google Scholar
  11. 11.
    Mul D, Hughes I. The use of GnRH agonist in precocious puberty. Eur J Endocrinol. 2008;159(S1):S3–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Partsch C, Sippell W. Treatment of central precocious puberty. Best Pract Res Clin Endocrinol Metab. 2002;16:165–89.CrossRefPubMedGoogle Scholar
  13. 13.
    Sathasivam A, Garibaldi L, Shapiro S, Godbold J, Rapaport R. Leuprolide stimulation testing for the evaluation of early female sexual maturation. Clin Endocrinol. 2010;73:375–81.CrossRefGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  • Anil Bhansali
    • 1
  • Anuradha Aggarwal
    • 2
  • Girish Parthan
    • 3
  • Yashpal Gogate
    • 4
  1. 1.Department of EndocrinologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia
  2. 2.Paras HospitalPatnaIndia
  3. 3.Renal MedicityCochinIndia
  4. 4.Harmony Health HubNasikIndia

Personalised recommendations